Literature DB >> 4027140

Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development.

C H Gleiter, G Aichele, E Nilsson, N Hengen, K H Antonin, P R Bieck.   

Abstract

The pharmacokinetics of CGP 15 210 G, a new 5-HT uptake inhibitor in poor and extensive metabolisers of debrisoquine, give indirect evidence of an association between its metabolism and polymorphic hydroxylation of the debrisoquine type.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4027140      PMCID： PMC1400618          DOI： 10.1111/j.1365-2125.1985.tb02802.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  6 in total

Review 1.  Polymorphisms of oxidation at carbon centers of drugs and their clinical significance.

Authors:  J R Idle; R L Smith
Journal:  Drug Metab Rev       Date:  1979       Impact factor: 4.518

2.  Protecting poor metabolizers, a group at high risk of adverse drug reactions.

Authors:  J R Idle; N S Oates; R R Shah; R L Smith
Journal:  Lancet       Date:  1983-06-18       Impact factor: 79.321

3.  Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection.

Authors:  M S Lennard; J H Silas; A J Smith; G T Tucker
Journal:  J Chromatogr       Date:  1977-03-11

4.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

5.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

6.  [Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population].

Authors:  B Dick; A Küpfer; J Molnàr; S Braunschweig; R Preisig
Journal:  Schweiz Med Wochenschr       Date:  1982-07-24
  6 in total
  3 in total

1.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 2.  Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics.

Authors:  K Brosen
Journal:  Clin Pharmacokinet       Date:  1990-03       Impact factor: 6.447

3.  Role of cytochrome P4502D6 in the metabolism of brofaromine. A new selective MAO-A inhibitor.

Authors:  N Feifel; K Kucher; L Fuchs; M Jedrychowski; E Schmidt; K H Antonin; P R Bieck; C H Gleiter
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.